Adverse outcome pathways - development and potential regulatory application

被引:1
|
作者
Rossi Lima, Thania Rios [1 ]
de Souza, Nathalia Pereira [1 ]
Pereira, Lilian Cristina [1 ,2 ]
Viana de Camargo, Joao Lauro [1 ]
机构
[1] Univ Estadual Paulista, Ctr Evaluat Environm Impact Human Hlth TOXICAM, Dept Pathol, Botucatu, SP, Brazil
[2] Univ Estadual Paulista, Sch Agr Sci, Dept Bioproc & Biotechnol, Botucatu, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Adverse Outcome Pathways; Hazard Assessment; Mode of Action; Risk Assessment; Regulatory Toxicology; BRADFORD-HILL CONSIDERATIONS; URINARY-BLADDER CARCINOGENS; CONCEPTUAL-FRAMEWORK; SCIENTIFIC CONFIDENCE; 21ST-CENTURY ROADMAP; IPCS FRAMEWORK; MODE; TOXICITY; SUPPORT; RELEVANCE;
D O I
10.22239/2317-269x.01835
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Over the last two decades, chemical safety assessment and regulatory toxicology have progressed from empirical science based on direct observation of apical adverse outcomes in whole organisms to a predictive practice that infers outcomes and risks on the basis of accumulated understanding of toxicological mechanisms and modes of action. Objective: To provide general concepts on how Adverse Outcome Pathways (AOPs) are developed and examples related to skin sensitization, endocrine disruption, and mitochondrial dysfunction. Method: Narrative review based on data of the scientific literature relevant to the theme addressed and on the experience of the authors. Results: An AOP framework provides a systematic approach to organize knowledge about mechanisms of toxicity that may inform analytical domains in regulatory decision-making. AOPs are open structures that may indicate not only data gaps in the understanding of a toxicity process, but also testing procedures that will generate the necessary knowledge to fill those gaps. Every AOP should be continuously refined through the collaborative efforts of the scientific community. Depending on the amount and detail of information that is successively inserted, AOP may progress from the stage of a putative AOP to the stages of qualitative and quantitative AOPs, which are more fit-for-purpose to support regulatory decision-making. Conclusions: Continuous collaboration between AOP developers within the scientific community and the regulatory corps toward the development of this mechanistic structure will support the advancement of toxicological sciences, regardless of its immediate application for regulatory purposes.
引用
收藏
页码:2 / 13
页数:12
相关论文
共 50 条
  • [41] Adverse outcome pathways: a concise introduction for toxicologists
    Vinken, Mathieu
    Knapen, Dries
    Vergauwen, Lucia
    Hengstler, Jan G.
    Angrish, Michelle
    Whelan, Maurice
    ARCHIVES OF TOXICOLOGY, 2017, 91 (11) : 3697 - 3707
  • [42] Adverse outcome pathways: a concise introduction for toxicologists
    Mathieu Vinken
    Dries Knapen
    Lucia Vergauwen
    Jan G. Hengstler
    Michelle Angrish
    Maurice Whelan
    Archives of Toxicology, 2017, 91 : 3697 - 3707
  • [43] Putative adverse outcome pathways relevant to neurotoxicity
    Bal-Price, Anna
    Crofton, Kevin M.
    Sachana, Magdalini
    Shafer, Timothy J.
    Behl, Mamta
    Forsby, Anna
    Hargreaves, Alan
    Landesmann, Brigitte
    Lein, Pamela J.
    Louisse, Jochem
    Monnet-Tschudi, Florianne
    Paini, Alicia
    Rolaki, Alexandra
    Schrattenholz, Andre
    Sunol, Cristina
    van Thriel, Christoph
    Whelan, Maurice
    Fritsche, Ellen
    CRITICAL REVIEWS IN TOXICOLOGY, 2015, 45 (01) : 83 - 91
  • [44] Development of an adverse outcome pathways approach for land resource and environment management at the regional scale
    Guo, Kai
    Liang, Xiaojin
    Zhang, Xinchang
    Luo, Renbo
    Qiu, Tianqi
    He, Zhenhao
    Zhang, Kexin
    ECOLOGICAL INDICATORS, 2023, 157
  • [45] Physiological maps: a benchmark tool for adverse outcome pathways and a cornerstone for the development of disease ontologies
    Staumont, B.
    Ladeira, L. C. M.
    Gamba, A.
    Lesage, R.
    Verhoeven, A.
    Jiang, J.
    Van Ertvelde, J.
    Barnes, D. A.
    Janssen, M. J.
    Kuchovska, E.
    Berkhout, J.
    Roodzant, D.
    Teunis, M.
    Bozada, T., Jr.
    Luechtefeld, T. H.
    Jover, R.
    Vanhaecke, T.
    Vinken, M.
    Masereeuw, R.
    Fritsche, E.
    Piersma, A. H.
    Heusinkveld, H. J.
    Geris, L.
    TOXICOLOGY LETTERS, 2022, 368 : S77 - S78
  • [46] The future trajectory of adverse outcome pathways: a commentary
    Sewell, Fiona
    Gellatly, Nichola
    Beaumont, Maria
    Burden, Natalie
    Currie, Richard
    de Haan, Lolke
    Hutchinson, Thomas H.
    Jacobs, Miriam
    Mahony, Catherine
    Malcomber, Ian
    Mehta, Jyotigna
    Whale, Graham
    Kimber, Ian
    ARCHIVES OF TOXICOLOGY, 2018, 92 (04) : 1657 - 1661
  • [47] Integration of adverse outcome pathways with knowledge graphs
    Schultz, B. T.
    Wehr, M.
    Witters, H.
    Escher, S.
    Jacobs, M.
    TOXICOLOGY LETTERS, 2022, 368 : S85 - S85
  • [48] Taking adverse outcome pathways to the next level
    Vinken, Mathieu
    TOXICOLOGY IN VITRO, 2018, 50 : A1 - A2
  • [49] The future trajectory of adverse outcome pathways: a commentary
    Fiona Sewell
    Nichola Gellatly
    Maria Beaumont
    Natalie Burden
    Richard Currie
    Lolke de Haan
    Thomas H. Hutchinson
    Miriam Jacobs
    Catherine Mahony
    Ian Malcomber
    Jyotigna Mehta
    Graham Whale
    Ian Kimber
    Archives of Toxicology, 2018, 92 : 1657 - 1661
  • [50] Review of Retinoid Signaling in Skeletal Development for Adverse Outcome Pathways and Predictive Toxicology Applications
    Pierro, J. D.
    Baker, N. C.
    Knudsen, T. B.
    BIRTH DEFECTS RESEARCH, 2020, 112 (11): : 854 - 855